The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $965,156 in first-year total cost, median $319,343.
Most frequent study sections
- Special Emphasis Panel[ZDA1 BSW-S (M2)]3
Most frequent institutions
- BIOINVENU CORPORATION1
- CONSEGNA PHARMA, INC.1
- DELIX THERAPEUTICS1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Long-acting injectable ketamine for improved substance use disorder (SUD) treatment without dissociative effects.1R43DA059056-01 | ZANA, LAWRENCE J | CONSEGNA PHARMA, INC., PA | $326,500 | ZDA1 |
| 2023 | New 5HT2AR Target Identification and Assay Development for Discovering Psychoplastogenic Compounds1R43DA059014-01 | EISHINGDRELO, HAIFENG | BIOINVENU CORPORATION, NJ | $319,343 | ZDA1 |
| 2023 | Determination of Route of Administration and Cardiac Safety of a Novel Psychoplastogen for the treatment of SUDs1R43DA059054-01 | MCTIGHE, STEPHANIE | DELIX THERAPEUTICS, CA | $319,313 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.